Meeting
2020 Gastrointestinal Cancers Symposium
Exploring telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.
Authors
Michael Morse
Duke University Medical Center, Durham, NC
Michael Morse , Eric Liu , Vijay N. Joish , Lynn Huynh , Mu Cheng , Todor Totev , Mei S. Duh , Pablo Lapuerta , David C. Metz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 618)
Abstract #
618
Poster Bd #
F21
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized, parallel arm, phase II study of telotristat (Xermelo) in combination with lutetium Lu 177 dotatate (Lutathera) in well-differentiated neuroendocrine tumors (NETs).
First Author: Aman Chauhan
Poster
2021 Gastrointestinal Cancers Symposium
Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.
First Author: Bernard Tawfik
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome.
First Author: Stacie Hudgens
Poster
2016 Gastrointestinal Cancers Symposium
Blood neuroendocrine tumor gene cluster analysis to predict somatostatin analog response.
First Author: Mark S. Kidd